CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

Abbott's Oncodetect test improves colorectal cancer recurrence detection sensitivity by 30 percentage points in study

By Public Technologies
  • Abbott presented Beta-CORRECT results at ESMO 2026 showing its whole-genome Oncodetect test improved detection of colorectal cancer recurrence versus its whole-exome version.
  • The test identified additional patients with residual cancer DNA following surgery, helping assess recurrence risk.
  • Detectable cancer DNA was the strongest predictor of recurrence among factors studied; further research will assess implications for patient management.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abbott Laboratories published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610230915PR_NEWS_USPR_____CG79251) on October 23, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk